Anastrazol (A) vs tamoxifen (T) vs combine (A+T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients

Semiglazov, V.; Semiglazov, V.V.; Иванов, В. Г.; Ziltzova, E.K.; Dashyan, G.A.; Kletzel, A.; Bozhok, A.A.; Нургазиев, К Ш; Tzyrlina, E.V.; Berstein, Lev M.

doi:10.1016/s0960-9776(03)80126-1

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies reporting the benefits of tamoxifen and, more recently, aromatase inhibitors as neoadjuvant treatment have been published, although to our knowledge there have been no studies comparing the use of neoadjuvant plus adjuvant therapy with adjuvant therapy alone. 4,[13][14][15][16][17][18][19] Aromatase inhibitors prevent estrogen biosynthesis by inhibiting the enzyme aromatase, which catalyzes the conversion of adrenal androgens (androstenedione and testosterone) to estrogens (estrone and estradiol). The triazole derivatives (e.g., anastrozole [Arimidex, AstraZeneca, Wilmington, DE]) are a new group of aromatase inhibitors, with combined potency and high selectivity for aromatase and have no discernible effects on adrenal function at the maximally effective aromatase inhibiting doses.…”

mentioning

confidence: 99%

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

Cataliotti

Buzdar

Noguchi

et al. 2006

Cancer

316

191

View full text Add to dashboard Cite

Although oxytocin (OT) and oxytocin receptor (OTR) are known for roles in parturition and milk let‐down, they are not hypothalamus‐restricted. OT is important in nurturing and opposition to stress. Transcripts encoding OT and OTR have been reported in adult human gut, and OT affects intestinal motility. We tested the hypotheses that OT is endogenous to the enteric nervous system (ENS) and that OTR signaling may participate in enteric neurophysiology. Reverse transcriptase polymerase chain reaction confirmed OT and OTR transcripts in adult mouse and rat gut and in precursors of enteric neurons immunoselected from fetal rats. Enteric OT and OTR expression continued through adulthood but was developmentally regulated, peaking at postnatal day 7. Coincidence of the immunoreactivities of OTR and the neural marker Hu was 100% in the P3 and 71% in the adult myenteric plexus, when submucosal neurons were also OTR‐immunoreactive. Co‐localization with NeuN established that intrinsic primary afferent neurons are OTR‐expressing. Because OTR transcripts and protein were detected in the nodose ganglia, OT signaling might also affect extrinsic primary afferent neurons. Although OT immunoreactivity was found only in ∼1% of myenteric neurons, extensive OT‐immunoreactive varicosities surrounded many others. Villus enterocytes were OTR‐immunoreactive through postnatal day 17; however, by postnatal day 19, immunoreactivity waned to become restricted to crypts and concentrated at crypt‐villus junctions. Immunoelectron microscopy revealed plasmalemmal OTR at enterocyte adherens junctions. We suggest that OT and OTR signaling might be important in ENS development and function and might play roles in visceral sensory perception and neural modulation of epithelial biology. J. Comp. Neurol. 512:256–270, 2009. © 2008 Wiley‐Liss, Inc.

show abstract

mentioning

confidence: 99%

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

Cataliotti

Buzdar

Noguchi

et al. 2006

Cancer

316

191

View full text Add to dashboard Cite

show abstract

“…Similar women with estrogen receptor-or progesterone receptor-positive tumors should be considered for preoperative endocrine therapy [28]. Previously, tamoxifen was the drug of choice for such patients; more recently, the aromatase inhibitors have proven to be superior to tamoxifen in this setting [29][30][31].…”

Section: Surgical Management Of Older Breast Cancer Patientsmentioning

confidence: 99%

The influence of aging on the early detection, diagnosis, and treatment of breast cancer

Siebel

Muss

2005

Curr Oncol Rep

View full text Add to dashboard Cite

Patterns of care for women with breast cancer vary substantially with patient age. Older patients with breast cancer frequently receive less than standard management, resulting in poorer outcome. At diagnosis, the health status of older women with breast cancer affects survival and treatment decisions. Age-related comorbidity may limit diagnostic tests, narrow treatment options, and significantly increase mortality not related to breast cancer. Yet, for healthy older women with early-stage breast cancer, stage-adjusted survival is similar to that of younger women. Calendar age is not sufficient to encompass the heterogeneity in health status of the elderly. Instead, management of older women with breast cancer should be based on anticipated survival, functional status, and the goals of the patient for treatment. In this review, we evaluate pertinent data and provide guidance for the management of older women with breast cancer.

show abstract

“…Although several pre‐operative trials comparing hormonal therapy with an aromatase inhibitor (AI) versus tamoxifen have reported the superior efficacy of AI in terms of primary tumor response, long‐term follow‐up outcomes from pre‐operative and subsequent post‐operative therapy have rarely been reported. ( 1–5 ) For instance, in the P024 neoadjuvant endocrine therapy trial, which compared 4 months’ pre‐operative letrozole versus tamoxifen, patients were treated with post‐operative tamoxifen only, regardless of the randomized pre‐operative treatment received. ( 6 ) Thus, it was not possible to evaluate the impact of a pre‐operative and subsequent post‐operative AI over tamoxifen on prognosis.…”

mentioning

confidence: 99%

Outcomes of Japanese breast cancer patients treated with pre‐operative and post‐operative anastrozole or tamoxifen

et al. 2012

View full text Add to dashboard Cite

The present study examined long-term efficacy outcomes in a subgroup of postmenopausal, estrogen receptor-positive Japanese breast cancer patients from the Pre-Operative ''Arimidex'' Compared with Tamoxifen trial, following pre-operative (3 months) and post-operative (5 years) adjuvant treatment with either anastrozole or tamoxifen. Patients with large, potentially operable, locally-advanced breast cancer were randomized to receive anastrozole (1 mg ⁄ day) plus tamoxifen placebo or tamoxifen (20 mg ⁄ day) plus anastrozole placebo pre-operatively. After surgery at 3 months, patients continued on the same study medication as adjuvant therapy for up to 5 years or until recurrence, intolerable toxicity or withdrawal of patient consent. Recurrencefree survival and overall survival were measured from the date of randomization to the date of recurrence or death, whichever occurred first. Patients were monitored for adverse events throughout the study period and up to 30 days following administration of the last study medication. During post-operative adjuvant therapy, 4 ⁄ 48 (8%) anastrozole and 25 ⁄ 49 (51%) tamoxifen patients experienced recurrence. There was a significant difference in recurrence-free survival between the two groups (hazard ratio 0.14; 95% confidence interval 0.05-0.41; P = 0.0003). There was a significant increase in overall survival with anastrozole (0.21; 0.05-0.96; P = 0.0436) and there were 2 ⁄ 48 (4%) and 10 ⁄ 49 (20%) deaths with anastrozole and tamoxifen, respectively. Most patients responding to pre-operative therapy remained recurrence-free. Sequential pre-operative ⁄ post-operative treatment with anastrozole resulted in lower recurrence and death rates, compared with tamoxifen. (Cancer Sci 2012; 103: 491-496) A lthough several pre-operative trials comparing hormonal therapy with an aromatase inhibitor (AI) versus tamoxifen have reported the superior efficacy of AI in terms of primary tumor response, long-term follow-up outcomes from pre-operative and subsequent post-operative therapy have rarely been reported.(1-5) For instance, in the P024 neoadjuvant endocrine therapy trial, which compared 4 months' pre-operative letrozole versus tamoxifen, patients were treated with post-operative tamoxifen only, regardless of the randomized pre-operative treatment received.(6) Thus, it was not possible to evaluate the impact of a pre-operative and subsequent post-operative AI over tamoxifen on prognosis.The Pre-Operative Arimidex Compared with Tamoxifen (PROACT) trial was a randomized, double-blind, doubledummy, multicenter study, conducted in the USA (12 centers), in Europe and the rest of the world (44 centers) and in Japan (25 centers) that compared anastrozole versus tamoxifen as pre-operative (12 weeks' treatment prior to primary surgery), in terms of objective response (OR), and subsequent post-operative (adjuvant) treatments in 451 postmenopausal women with large, operable, or potentially operable, locally-advanced, hormone receptor-positive (HR+) breast cancer. PROACT demonstrated that anas...

show abstract

Anastrazol (A) vs tamoxifen (T) vs combine (A+T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients

Cited by 3 publications

References 0 publications

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

The influence of aging on the early detection, diagnosis, and treatment of breast cancer

Outcomes of Japanese breast cancer patients treated with pre‐operative and post‐operative anastrozole or tamoxifen

Contact Info

Product

Resources

About